Android app on Google Play

Amarin (AMRN) Issused Patent 8,324,195 for Vascepa

December 4, 2012 7:33 AM EST Send to a Friend
Amarin Corp Plc (NASDAQ: AMRN) announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering Amarin's Vascepa® (icosapent ethyl) capsules based on U.S. Patent Application Serial No. 13/349,150. On September 10, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No.8,324,195, has a term that expires no earlier than in 2030.

"This patent issuance represents yet another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."

Amarin now has 10 U.S. patents either issued or allowed as well as over 30 additional patent applications currently in prosecution in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment